



Clinical Article

Prevalence and risk factors of *Ureaplasma urealyticum* and *Mycoplasma genitalium* among women with secondary infertility in Vietnam – A cross-sectional study

Tam Minh Le^{ab*}, Do Quang Le^b, Huy Vu Quoc Nguyen^b, Tram Viet Quynh Ngo^c, Bach Hoang Nguyen^c

^aCenter for Reproductive Endocrinology and Infertility, Hue University Hospital, Hue University, Hue City, Vietnam;

^bDepartment of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy, Hue University, Hue City, Vietnam;

^cDepartment of Microbiology, Hue University of Medicine and Pharmacy, Hue University, Hue City, Vietnam.

Received December 27, 2019; Revised February 10, 2020; Accepted April 20, 2020

Abstract: Introduction: *Ureaplasma urealyticum* and *Mycoplasma genitalium* are infectious pathogens resulting in non-gonococcal urethritis and complications such as pelvic inflammatory disease (PID) and infertility. This study aimed to determine the prevalence of *U. urealyticum* and *M. genitalium* in women with secondary infertility and the related factors to these infections. **Methods:** This cross-sectional descriptive study was carried out from July 2017 to June 2018. Cervical specimens were collected from women with secondary infertility at the Center for Reproductive Endocrinology and Infertility, Hue University Hospital, Vietnam. PCR was applied for detection of *U. urealyticum* and *M. genitalium*. Tubal patency was assessed by hysterosalpingography. **Results:** Prevalence of *U. urealyticum* and *M. genitalium* were 37.9% and 2.1%, respectively. The association was not statistically significant among infection and the following factors like age, educational level, occupation, history of miscarriage, history of genital infection and abdominal surgery, or infertility duration ($p > 0.05$). There was a statistically significant correlation between *U. urealyticum* infection and tubal damage according to hysterosalpingography ($p < 0.05$). **Conclusion:** In the case of women with secondary infertility, genital infection with *M. genitalium* was rare, whereas that with *U. urealyticum* infection was high and appeared to be associated with tubal damage.

Keywords: *Ureaplasma urealyticum*; *Mycoplasma genitalium*; infertility; tubal disorder; hysterosalpingography.

1. INTRODUCTION

Secondary infertility is defined as unable to get a clinical pregnancy after one year of unprotected sexual intercourse in couples with a history of at least one pregnancy, birth, miscarriage, planned abortion, or ectopic pregnancy [1]. Infertility impacts on financial burden on patients and the health care system as well as in psychological aspect for millions of couples [2]. Among the major causes of female infertility, endocrine or ovulatory dysfunction together with

uterine or peritoneal diseases are most common, whereas tubal disorder is the second common causes of secondary infertility in women [3].

Pelvic inflammatory disease (PID) is one of the most important causes of tubal disorder leading to infertility. Beside *Neisseria gonorrhoea* and *Chlamydia trachomatis* playing as the two mostly frequently associated to upper genital tract infections [4], the female genital tract is an appropriate environment for the growth of other pathogenic

*Address correspondence to Minh Tam Le, M.D.,Ph.D, Associate Professor at Department of Obstetrics and Gynecology, Hue University of Medicine and Pharmacy, Hue University, Hue City, Vietnam; Tel/Fax: 0084.989228779; E-mails: leminhnam@huemed-univ.edu.vn
 DOI: 10.32895/UMP.MPR.4.2.3

and non-pathogenic microorganisms. *Mycoplasma* is a bacterium that can cause asymptomatic to minimally symptomatic genital tract infections but can result in chronic complications, including infertility. Previous published studies have shown that *Ureaplasma urealyticum* and *Mycoplasma genitalium* are responsible for lower genital tract infections (vulvovaginitis) as well as upper genital tract infections such as endometritis and pelvic inflammatory disease [5-7]. *M. genitalium* was detected by swab from the cervix in 19.6% of all infertile and in 4.4% of fertile women [7]. Furthermore, the pregnancy rate after elimination of *U. urealyticum* was significantly improved [5]. Pelvic inflammatory disease caused by these bacteria can induce tubal disorders of varying degrees, including tubal occlusion or hydrosalpinx.

U. urealyticum primarily colonizes in the human urogenital tract and in the vaginal flora but it does not cause disease under normal conditions, except when immunity is impaired or the vaginal mucosa is damaged. However, the impact of these infections to female infertility is still unclear. Some authors reported that *U. urealyticum* and *M. genitalium* may cause potential pathological effects on fertility in women [5, 8], while other research has indicated no relation [9]. Whether *U. urealyticum* and *M. genitalium* are responsible partly for infertility or whether this relationship is only coincidental remains an unanswered question.

Currently, it is not recommended for routine screening of asymptomatic individuals for *Mycoplasma hominis*, *U. urealyticum*, and *U. parvum*, because the asymptomatic presence of these bacteria does not always develop disease. However, cases with a high *U. urealyticum* load may benefit from treatment [10]. The widely indication of these testing, diagnosis and accordingly treatment of these bacteria may result in economic burden [10]. However, while detection via PCR at a certain time cannot be causally linked to prior damage, the presence of *M. genitalium* or *U. urealyticum* may be associated with prior infection with a traditional sexually transmitted urethritis-inducing agent, such as *Neisseria gonorrhoeae* or *Chlamydia trachomatis*, which may be related to secondary infertility. Furthermore, new techniques of molecular methods have made the detection of *U. urealyticum* and *M. genitalium* more feasible at high sensitivity and specificity. So far, the recommendation of screening *U. urealyticum* or *M. genitalium* to prevent the complication of PID with severe tubal damage is still controversial. The present study aimed to determine the prevalence of *U. urealyticum* and *M. genitalium* infections in cervical samples from secondarily infertile women and their relationship to fallopian tube disorders.

2. MATERIALS AND METHOD

2.1. Study population

Women with secondary infertility who underwent treatment at the Center for Reproductive Endocrinology & Infertility, Hue University Hospital, from July 2017 to July 2018 were enrolled for a cross-sectional descriptive study. Inclusion criteria included women who were unable to get clinical pregnant after 12 months of active sexual intercourse or the inability to get a full-term pregnancy until a live

birth. Exclusion criteria included being treated for genital tract infection with local or systematic antibiotics within 4 weeks prior to inclusion, menorrhagia or declining enrollment. The local ethics committee of Hue University of Medicine and Pharmacy has approved this study, registration number H2016/243. All participants were explained and requested for written informed consent.

2.2. Survey method

All recruited women were interviewed following a prepared protocol to obtain general characteristics including age, occupation, geography, history of miscarriage, and history of genital tract infection. A standardized pelvic examination was then performed, and one vaginal swab was taken for direct microscopic examination by wet mount. One endocervical sample was also collected for detection of *U. urealyticum* and *M. genitalium* by PCR.

Hysterosalpingograms (HSGs) were indicated and assessed by experienced doctors in all cases to investigate the cavity of the uterus and fallopian tubes. First, a standard image was obtained before the injection of contrast (Ultravist 300 (iopromide), Bayer, Leverkusen, Germany). Four images were taken to assess the uterine cavity, tubal patency, and the appearance of contrast medium in the pelvic cavity.

2.3. Laboratory test

Total DNA from the vaginal swab samples were performed using iVApDNA Extraction Kit (Viet A Technology Corp., Ho Chi Minh, Vietnam), following the manufacturer's instruction. The quality of total DNA were checked using a NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Conventional PCR was performed using primers specifically targeting 540 bp of the urease gene of *U. urealyticum* and 281 bp of the adhesin gene of *M. genitalium* [11-14].

U. urealyticum

forward: 5'-AGAAGACGTTTAGCTAGAGG-3'

forward: 5'-AGTTGATGAAACCTTAACCCCTTGG-3'

M. genitalium

reverse: 5'-ACGACGTCCATAAGCAACT-3'

reverse: 5'-CCGTTGAGGGGTTTCCATTTTGC-3'

A total reaction volume reaction 25- μ L reaction contained 5 μ L DNA template, 0.4 μ M each primer, and 12.5 μ L 2 \times GoTaq Green Master Mix (Promega, Madison, WI, USA). PCR conditions for detection of *U. urealyticum* were as follows: initial denaturation at 95°C for 4 min, 36 cycles of 95°C for 50 s, 55°C for 50 s, and 72°C for 60 s. Those for detection of *M. genitalium* were as follows: initial denaturation at 95°C for 5 min, followed by 36 cycles of 95°C for 30 s, 65°C for 30 s, and 72°C for 30 s. PCRs were performed on a Veriti™ 96-Well Thermal Cycler (Thermo Fisher Scientific). PCR products were separated by 1% agarose gel electrophoresis containing 1 \times GelRed™ (Biotium, Fremont, CA, USA) and digitalized with a Gel Doc XR System (Bio-Rad, Hercules, CA, USA).

2.4. Data analysis

All analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA). An independent sample *t*-test was used for normally distributed data or the Mann–Whitney *U*-test for skewed data in comparison of continuous variables between groups., the chi-square or Fisher's exact test were used for comparing categorical variables. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). *p* value under 0.05 were considered significant statistically.

3. RESULTS

Table 1. Socio-demographic characteristics and gynecologic examination of secondary infertile women

Characteristics	Number (n=95)	Percent (%)
Age		
< 35	67	70.5%
≥ 35	28	29.5%
Mean±SD	32.36 ± 4.72	
Occupation		
Manual work	41	43.2%
Office work	54	56.8%
Geography		
Urban	35	36.8%
Non-urban	60	63.2%
Educational levels		
School grade	38	40%
College / University grade	57	60%
Infertility duration		
< 3 years	37	38.9%
≥ 3 years	58	61.1%
History of GTI		
Yes	22	23.2%
No	73	76.8%
History of miscarriage		
Yes	60	63.2%
No	35	36.8%
Wet-mount results		
Normal microbiota	70	73.7%
Abnormal	25	26.3%
Bacterial vaginosis	17	17.9%
Candidiasis	7	7.4%
Trichomoniasis	1	1.1%
Aerobic vaginitis*	2	2.1%

GTI: genital tract infection

*Two cases of aerobic vaginitis were co-infected with Candidiasis

By screening all women with secondary infertility who were treated at the Center for Reproductive Endocrinology &

Infertility, Hue University Hospital, from July 2017 to July 2018, total of 95 cases were satisfied inclusion criteria with mean age of 32.36 ± 4.72, 56.8% work in office, 63.2% lives in non-urban area, 60% has educational levels from college grade and 61.1% is secondary infertility more than three years. There is 23.2% women with history of GTI and 63.2% with history of miscarriage. Table 1 also shows that 73.7% of patients had a normal vaginal microbiota. Among the 25 cases with abnormal wet-mount, the most frequent infection type was bacterial vaginosis (17.9%), with candidiasis accounting for 7.4% of cases, aerobic vaginitis accounting for 2%, and trichomoniasis accounting for 1.1%. Two cases of aerobic vaginitis are co-infected with Candidiasis.

According to PCR of cervical samples from 95 secondarily infertile women, we detected 36 cases (37.9%) positive for *U. urealyticum* and only two cases (2.1%) positive for *M. genitalia* (Figure 1). There was no statistically significant association between groups with positive PCR for *U. urealyticum* as well as group with positive PCR for *M. genitalium* and age, geography, occupation, education level, history of genital tract infection, history of abdominal surgery, or history of miscarriage, as shown in Table 3. Positive PCR result for *U. urealyticum* was found to be associated with bacterial vaginosis, with 2.86 times of higher rate of co-infection (95% CI: 0.976–8.367, *p* = 0.05) while the two cases positive for *M. genitalium* had normal vaginal microbiota.

Table 2. Hysterosalpingography results in secondary infertile women

Hysterosalpingography results	n	%
Women with normal tubes	64	67.4
Occlusion 1 side	13	13.7
Occlusion 2 sides	9	9.5
Hydrosalpinx 1 side	5	5.3
Hydrosalpinx 2 sides	2	2.1
Occlusion 1 side and Hydrosalpinx 1 side	2	2.1
Total	95	100

Among the 95 cases, normal HSG results were recorded in 64 cases, accounting for 67.4% of patients. Tube occlusion on one or both sides was observed in 13.6% and 9.5% of cases, respectively, and hydrosalpinx on one or both sides was observed in 5.3% and 2.1% of cases, respectively (Table 2). Analysis showed that a positive PCR result for *U. urealyticum* was correlated with an abnormal HSG in secondarily infertile women, increasing the rate of an abnormal HSG result by 2.88-fold (95% CI: 1.18–6.99, *p* = 0.018) (Table 4).

4. DISCUSSION

U. urealyticum and *M. genitalium* have been reported to be associated with female infertility in some studies [15, 16]. *M. genitalium* has been detected in 5.7% (10/176) of the total population and in 5.6% (9/161) of those with symptoms, corresponding to 5.7% (5/87) of symptomatic men and 5.4% (4/74) of symptomatic women [17]. *Ureaplasma* was also diagnosed in 25.8% of patients with genital tract infections and 20.8% of infertile women [18]. According to Peerayeh et

al., 30.7% of infertile women were positive for *Ureaplasma* or *Mycoplasma*, among which 51.7% were positive for *Ureaplasma*, 26.7% for *Mycoplasma*, and 21.5% for both [19]. Similarly, Grzesko *et al.* found a prevalence of *M.*

genitalium infection of 19.6% in infertile women [5]. A population-based study of *M. genitalium* in Vietnam reported a significantly low prevalence in reproductive age women in rural areas (0.8%; 95% confidence interval, 0.25–1.35%) [20].

Table 3. Prevalence and the risk factors of positive PCR for *U. urealyticum* and *M. genitalium* in secondary infertile women

Characteristics	Positive PCR for <i>U. urealyticum</i> n=36		p-value	Positive PCR for <i>M. genitalium</i> n=2		p-value
	n / Total (%)	OR (95% CI)*		n / Total (%)	OR (95% CI)*	
Age						
< 35	24 (35.8)	0.74	0.415	2 (3.0%)	-	1
≥ 35	12 (42.9%)	[0.30-1.83]		0		
Occupation						
Manual work	13 (31.7%)	1.60	1.17	1 (2.4%)	0.76	1
Office work	23 (42.6%)	[0.68-3.74]		1 (1.9%)		
Geography						
Urban	15 (42.9%)	1.39	0.58	0	-	0.53
Non-urban	21 (35.0%)	[0.59-3.27]		2 (3.3%)		
Educational levels						
School grade	12 (31.6%)	0.64	0.30	1 (2.6%)	1.51 [0.09-24.96]	1
College / University grade	24 (42.1%)	[0.27-1.50]		1 (1.8%)		
Infertility duration						
< 3 years	15 (40.5%)	1.201	0.18	1 (2.7%)	1.583	1
≥ 3 years	21 (36.2%)	[0.52-2.80]		1 (1.7%)		
History of GTI						
Yes	10 (45.5%)	1.51	0.695	1 (4.5%)	3.43	0.41
No	26 (35.6%)	[0.57-3.96]		1 (1.4%)		
History of miscarriage						
Yes	22 (36.7%)	0.868	0.104	2 (3.3%)	-	0.53
No	14 (40.0%)	[0.37-2.04]		0		
Wet-mount results						
Normal microbiota	23 (32.9%)			2 (100%)		
Abnormal	13 (52%)			0		
Bacterial vaginosis	10 (58.8%)	2.857 [0.976-8.367]	0.05			
Candidiasis	2 (28.6%)	0.653 [0.117-3.460]	0.706			
Trichomoniasis	1 (100%)		0.379			
Aerobic vaginitis **	2 (100%)		0.141			

U. urealyticum: *Ureaplasma urealyticum*; *M. genitalium*: *Mycoplasma genitalium*; *GTI*: genital tract infection

* non-adjusted odds ratio; ** these 2 cases of aerobic vaginitis were detected in coinfection with Candidiasis.




Figure 1. PCR amplification analysis for the detection of (A) *U. urealyticum* and (B) *M. genitalium*. PCR products were separated on a 1.0% agarose gel. Lane SM is a DNA size marker (GeneRuler 100 bp DNA Ladder - Thermo Fisher Scientific); in lane PC, *M. genitalium* (ATCC® 33530D™) and *U. urealyticum* (ATCC® 29559™) were used as positive controls; lane NC is a non-template control; lanes 3–8 are genomic DNAs from vaginal swab samples.

Table 4. Correlation between PCR-positive cases for *U. Urealyticum* and *M. genitalium* and hysterosalpingography results

Genital tract infection	Abnormal HSG		Normal HSG		p*-value	OR (95% CI)
	n	%	n	%		
<i>U. urealyticum</i>						
Positive	17	47.2	19	52.8	0.018	2.88 [1.18- 6.99]
Negative	14	23.7	45	76.5		
<i>M. genitalium</i>						
Positive	0		2	100	1	
Negative	31	33.3	62	66.7		
Total	31	32.6	64	67.4		

HSG: hysterosalpingography

Our study revealed that the prevalences of *U. urealyticum* and *M. genitalium* in cervical samples of secondarily infertile patients were 37.9% and 2.1%, respectively. Compared to community studies of infertile individuals, this shows a similar or higher prevalence of *U. urealyticum* infection. Atefeh *et al.* reported similar results, with prevalence of *U. urealyticum* and *M. genitalium* of 37.5% and 2.9% in 104 infertile women [21]. Sleha *et al.* found that the prevalence of *U. urealyticum* infection in 111 infertile women was 39.6% [22], and Melih *et al.* found that a *U. urealyticum* infection rate of 42% among women with unexplained infertility [6]. Seifoleslami *et al.* found that the prevalence of *U. urealyticum* in infertile women was significantly higher than that in women without infertility [3], and this pattern was also observed in a study by Al-Kayat with 150 infertile and 150 non-infertile women showing prevalences of 22% and 4.7%, respectively [5]. Grzeško *et al.* reported that subjects with vaginal discharge showed a significantly higher incidence of *U. urealyticum* than the asymptomatic group [7]. A study by Benu *et al.* in adult women with abnormal discharge revealed that the prevalence of *U. urealyticum* infection as detected by PCR was 45% [18].

In fact, as demonstrated by the abovementioned studies, research has shown a high prevalence of *U. urealyticum* in cervical swabs. However, there is less evidence determining the relationship between the presence of a microorganism as detected by PCR of a sample taken at a given time and an

acute infection. According to Horner *et al.*, routine testing of asymptomatic persons for *U. urealyticum* is not recommended. This is because detection by PCR shows the presence of a microorganism but does not confirm an infection and therefore cannot indicate whether the microorganism has caused tubal damage prior to testing for infertility [10].

In our study, among women with a positive PCR result for *U. urealyticum*, the prevalence of an abnormal HSG result was 47.2%, while in women without a positive *U. urealyticum* result, the prevalence of an abnormal HSG was only 23.7%. The two patients with *M. genitalium* infection had normal HSGs. There was a statistically significant relation between *U. urealyticum* infection and an abnormal HSG. An early study by Henry-Suchet *et al.* performed laparoscopic examination on 99 women in three groups: (1) 17 with acute pelvic inflammatory disease, (2) 46 with tubal infertility without pelvic inflammatory disease, and (3) a control group of 36 women with infertility due to other causes [23]. The results showed that *U. urealyticum* was present in 17% of the specimens collected from the fallopian tubes or peritoneum of the experimental groups and only 5% of those from the control group. Among infertile women with occluded fallopian tubes, the prevalence of *U. urealyticum* infection was five times higher than that of the infertile women with normal tubes, but this difference was not statistically significant [24]. A study in Spain found that in infertile women, *Ureaplasma* infection rates were 21.7%, and among 10 cases with *Ureaplasma*

present, an abnormal HSG was recorded in seven cases [25]. However, this statistically difference was not significant due to the small sample size.

Studies on *M. genitalium* have also shown high infection rates in infertile patients. A study by Nonika and colleagues in women with infertility in India showed that the prevalence of *M. genitalium* infection was 16% among specimens from the urine, cervix, or endometrium, while no infections were detected in non-infertile women [26]. Rates of occlusion and endometrial hyperplasia were 33% and 26.66%, respectively, among those positive for *M. genitalium* [26]. Svenstrup *et al.* studied 194 women with tubal disease and showed that 17% of patients had anti-*M. genitalium* antibodies, compared with only 4% of women with normal uterine tubes; additionally, 14% of patients with a history of pelvic inflammatory disease were positive for *M. genitalium*, compared with 6% of patients with no history of PID [27]. However, in our study, only 2/95 women with secondary infertility were positive for *M. genitalium*, so it was not possible to assess associations with other factors.

Limitation of the current study is that the detection of *M. genitalium* and *U. urealyticum* by PCR will show the presence of a microorganism but not infection and not ensure that the microorganism has caused tubal damage prior to testing for infertility. Therefore, it would be more relevant to test for antibodies to the microorganisms of interest, as the presence of antibodies would indicate a previous infection. In addition, abnormal HSG findings could also be caused by other co-infections not tested for, such as *C. trachomatis* and *N. gonorrhoeae*.

In conclusion, previous research has revealed important complications involving *U. urealyticum* and *M. genitalium* infection, but prevalence appears to vary in different populations. Our data showed that in secondarily infertile women, the presence of *M. genitalium* was rare whereas the proportion positive for *U. urealyticum* according to PCR was high. The presence of this bacterium may be associated with tubal damage. It is therefore necessary to routinely screen for *U. urealyticum* for better diagnosis and management of secondary infertility.

5. CONCLUSION

In the case of women with secondary infertility, genital infection with *M. genitalium* was rare, whereas that with *U. urealyticum* infection was high and appeared to be associated with tubal damage.

AUTHOR CONTRIBUTIONS

M.T.L, Q.D.L, V.Q.H.N participated in the study design, execution, analysis, manuscript drafting and critical discussion. V.Q.T.N, H.B.N, participated in the study execution, manuscript drafting and critical discussion. All authors have read and approved the final manuscript.

ACKNOWLEDGEMENTS

This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sectors.

CONFLICTS OF INTEREST

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

REFERENCES

- Zegers-Hochschild F, Adamson GD, Dyer S, et al. The international glossary on infertility and fertility care. *Fertil Steril.* 2017;108:393-406.
- Cousineau TMD, Alice D. Psychological impact of infertility. *Clin Obstet Gynecol.* 2006;21:293-308.
- National Collaborating Centre for Women's and Children's Health (UK). Investigation of fertility problems and management strategies. In: *Fertility: Assessment and Treatment for People with Fertility Problems.* London: Royal College of Obstetricians & Gynaecologists. 2013; <https://www.ncbi.nlm.nih.gov/books/NBK327770/>.
- Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impact on human reproduction. *Human Reproduction.* 1999;5(5):433-47.
- Al-Kayat ES. Prevalence of two species of genital mycoplasmas among infertile women attended to infertility clinic in Thi-Qar. *Thi-Qar Med J.* 2015;10:57-67.
- Güven MA, Dilek U, Pata O, Dilek S, Cirağil P. Prevalence of Chlamydia trachomatis, Ureaplasma urealyticum and Mycoplasma hominis infections in the unexplained infertile women. *Arch Gynecol Obstet.* 2007;276:219-23.
- Grzeško J, Elias M, Mączynska B, Kasprzykowska U, Tłaczała M, Goluła M. Occurrence of Mycoplasma genitalium in fertile and infertile women. *Fertil Steril.* 2009;91:2376-80.
- Seifoleslami M, Safari A, Khameneie MK. Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in high vaginal swab samples of infertile females. *Iranian Red Crescent Medical Journal.* 2015;17:12.
- Fencki V, Yilmazer M, Aktepe OC. Have Ureaplasma urealyticum and Mycoplasma hominis infections any significant effect on female fertility. *Infezioni in Medicina.* 2002;10:220-3.
- Horner P, Donders G, Cusini M, Gomberg M, Jensen JS, Unemo M. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women?—a position statement from the European STI Guidelines Editorial Board. *J Eur Acad Dermatol Venereol.* 2018;32:1845-51.
- Malaguti N, Bahls LD, Uchimura NS, Gimenes F, Consolaro MEL. Sensitive detection of thirteen bacterial vaginosis-associated agents using multiplex polymerase chain reaction. *BioMed Res Int.* 2015;2015:645853.
- Martinelli F, Garrafa E, Turano A, Caruso A. Increased frequency of detection of Ureaplasma urealyticum and Mycoplasma genitalium in AIDS patients without urethral symptoms. *J Clin Microbiol.* 1999;37:2042-4.
- Musatovova O, Baseman JB. Analysis identifying common and distinct sequences among Texas clinical strains of Mycoplasma genitalium. *J Clin Microbiol.* 2009;47:1469-75.
- Riley DE, Samadpour M, Krieger JN. Detection of variable DNA repeats in diverse eukaryotic microorganisms by a single set of polymerase chain reaction primers. *J Clin Microbiol.* 1991;29:2746-51.
- Peerayeh SN, Yazdi RS, Zeighami H. Association of Ureaplasma urealyticum infection with varicocele-related infertility. *J Infect Dev Ctries.* 2008;2:116-9.
- Miron ND, Socolov D, Mares M, et al. Bacteriological agents which play a role in the development of infertility. *Acta Microbiol Immunol Hung.* 2013;60:41-53.
- Chra P, Papaparaskavas J, Papadogeorgaki E, et al. Prevalence of Mycoplasma genitalium and other sexually-transmitted pathogens among high-risk individuals in Greece. *Germs.* 2018;8:12-20.
- Dhawan B, Gupta V, Khanna N, Singh M, Chaudhry R. Evaluation of the diagnostic efficacy of PCR for Ureaplasma urealyticum infection in Indian adults with symptoms of genital discharge. *Jpn J Infect Dis.* 2006;59:57-8.
- Peerayeh SN, Sattari M. Detection of Ureaplasma urealyticum and Mycoplasma hominis in endocervical specimens from infertile women by polymerase chain reaction. *Middle East Fertil Soc J.* 2006;11:104-8.

20. Olsen B, Lan P, Stålsby Lundborg C, Khang T, Unemo M. Population-based assessment of *Mycoplasma genitalium* in Vietnam – low prevalence among married women of reproductive age in a rural area. *J Eur Acad Dermatol Venereol.* 2009;23:533-7.
21. Mousavi A, Farhadifar F, Mirnejad R, Ramazanzadeh R. Detection of genital mycoplasmal infections among infertile females by multiplex PCR. *Iran J Microbiol.* 2014;6:398-403.
22. Sleha R, Boštíková V, Hampl R, et al. Prevalence of *Mycoplasma hominis* and *Ureaplasma urealyticum* in women undergoing an initial infertility evaluation. *Epidemiol Mikrobiol Imunol.* 2016;65:232-7.
23. Henry-Suchet J, Catalan F, Loffredo V, et al. Microbiology of specimens obtained by laparoscopy from controls and from patients with pelvic inflammatory disease or infertility with tubal obstruction: *Chlamydia trachomatis* and *Ureaplasma urealyticum*. *Am J Obstet Gynecol.* 1980;138:1022-5.
24. Urdaneta JM, Cantillo EH, Alarcón AS, et al. Infertilidad tubárica e infección genital por *Chlamydia trachomatis*-*Ureaplasma urealyticum*. *Rev Chil Obstet Ginecol.* 2013;78:32-43.
25. Hernández-Marín I, Aragón-López CI, Aldama-González PL, Jiménez-Huerta J. Prevalence of infections (*Chlamydia*, *Ureaplasma* and *Mycoplasma*) in patients with altered tuboperitoneal factor. *Ginecol Obstet Mex.* 2016;84:14-8.
26. Rajkumari N, Kaur H, Roy A, Gupta N, Dhaliwal LK, Sethi S. Association of *Mycoplasma genitalium* with infertility in North Indian women. *Ind J Sex Transm Dis AIDS.* 2015;36:144-8.
27. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. *Mycoplasma genitalium*, *Chlamydia trachomatis*, and tubal factor infertility—a prospective study. *Fertil Steril.* 2008;90:513-20.